<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 1999
Or
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
COMMISSION FILE NUMBER: 0-26190
AMERICAN ONCOLOGY RESOURCES, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 84-1213501
(State or other jurisdiction of incorporation or (I.R.S. EMPLOYER
organization) Identification No.)
16825 NORTHCHASE DRIVE, SUITE 1300
HOUSTON, TEXAS
77060
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
(ZIP CODE)
(281) 873-2674
(REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes [X] NO [_]
As of May 6, 1999, 35,627,773 shares of the Registrant's Common Stock were
outstanding. In addition, as of May 6, 1999, the Registrant had agreed to
deliver 13,639,990 shares of its Common Stock on certain future dates for no
additional consideration.
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
FORM 10-Q
MARCH 31, 1999
TABLE OF CONTENTS
Page No.
--------
PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
Condensed Consolidated Balance Sheet 3
Condensed Consolidated Statement of Operations 4
Condensed Consolidated Statement of Stockholders' Equity 5
Condensed Consolidated Statement of Cash Flows 6
Notes to Condensed Consolidated Financial Statements 7
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations 13
Item 3. Quantitative and Qualitative Disclosures About Market Risks 19
PART II. OTHER INFORMATION
Item 2. Changes in Securities 20
Item 6. Exhibits and Reports on Form 8-K 21
SIGNATURES 22
-2-
<PAGE>
PART I. FINANCIAL INFORMATION
ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
AMERICAN ONCOLOGY RESOURCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEET
(in thousands, except par value and share amounts)
<TABLE>
<CAPTION>
MARCH 31, DECEMBER 31,
1999 1998
---------------- -----------------
ASSETS (UNAUDITED)
<S> <C> <C>
Current assets:
Cash and equivalents....................................................... $ 4,089 $ 10,618
Accounts receivable........................................................ 158,046 133,465
Prepaids and other current assets.......................................... 19,696 14,006
Due from affiliated physician groups....................................... 6,588 13,527
----------- -----------
Total current assets.................................................. 188,419 171,616
Property and equipment....................................................... 83,210 75,266
Less-accumulated depreciation and amortization.............................. (25,231) (21,776)
----------- -----------
57,979 53,490
Management service agreements, net of amortization of $31,609 and $27,459.... 379,918 338,673
Other assets................................................................. 6,305 4,321
----------- -----------
$ 632,621 $ 568,100
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current maturities of long-term indebtedness............................. $ 16,525 $ 14,708
Accounts payable......................................................... 34,453 48,207
Due to affiliated physician groups....................................... 5,920 1,799
Accrued compensation costs............................................... 4,022 4,381
Accrued interest payable................................................. 4,419 4,408
Income taxes payable..................................................... 9,955 6,435
Other accrued liabilities................................................ 15,167 9,662
----------- -----------
Total current liabilities............................................. 90,461 89,600
Deferred income taxes........................................................ 11,465 10,973
Long-term indebtedness....................................................... 211,824 173,140
----------- -----------
Total liabilities..................................................... 313,750 273,713
----------- -----------
Stockholders' equity:
Preferred Stock, $.01 par value, 1,000,000 shares authorized, none
issued and outstanding.................................................
Series A Preferred Stock, $.01 par value, 500,000 shares authorized and
reserved, none issued and outstanding..................................
Common Stock, $.01 par value, 80,000,000 shares authorized, 33,576,466 and
32,749,222 issued and 33,576,466 and 32,373,922 outstanding............. 336 328
Additional paid-in capital................................................. 148,305 148,425
Common Stock to be issued, 15,684,697 and 15,540,928 shares............... 83,383 70,643
Treasury Stock, 375,300 shares.............................................
(3,696)
Retained earnings.......................................................... 86,847 78,687
----------- -----------
Total stockholders' equity............................................ 318,871 294,387
----------- -----------
$ 632,621 $ 568,100
=========== ===========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT.
-3-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(in thousands, except per share data)
(UNAUDITED)
<TABLE>
<CAPTION>
THREE MONTHS
ENDED MARCH 31,
-------------------------
1999 1998
-------- --------
<S> <C> <C>
Revenue................................................. $139,840 $100,949
Operating expenses:
Pharmaceuticals and supplies.......................... 67,644 45,109
Practice compensation and benefits.................... 25,800 19,459
Other practice costs.................................. 14,680 11,809
General and administrative............................ 6,581 6,041
Depreciation and amortization.................... 7,856 4,490
-------- --------
122,561 86,908
-------- --------
Income from operations.................................. 17,279 14,041
Other income (expense):
Interest income....................................... 60 29
Interest expense...................................... (3,602) (2,988)
-------- --------
Income before income taxes.............................. 13,737 11,082
Income taxes............................................ 5,220 4,211
-------- --------
Net income and comprehensive income..................... $ 8,517 $ 6,871
======== ========
Net income per share - basic............................ $0.17 $0.14
======== ========
49,218 47,959
Shares used in per share calculations - basic........... ======== ========
Net income per share - diluted.......................... $0.17 $0.14
======== ========
50,548 49,940
Shares used in per share calculations - diluted......... ======== ========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT.
-4-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
(in thousands)
(unaudited)
<TABLE>
<CAPTION>
COMMON STOCK ADDITIONAL COMMON TREASURY
------------------ PAID-IN STOCK TO STOCK RETAINED
SHARES PAR VALUE CAPITAL BE ISSUED COST EARNINGS TOTAL
------ --------- ----------- ---------- --------- --------- --------
<S> <C> <C> <C> <C> <C> <C> <C>
Balance at December 31, 1998.......... 32,749 $328 $148,425 $70,643 $(3,696) $78,687 $294,387
Medical practice transactions-value
of 1,336,507 shares to be issued..... 15,951 15,951
Delivery of 375,300 shares of
Common Stock to be issued
from Treasury........................ (1,696) (1,643) 3,696 (357) -
Delivery of 817,438 shares from
Issuance of Common Stock............. 817 8 1,560 (1,568) -
Exercise of options to purchase
Common Stock......................... 10 16 16
Net income and comprehensive
Income............................... 8,517 8,517
------ --------- -------- --------- -------- -------- --------
Balance at March 31, 1999............. 33,576 $336 $148,305 $ 83,383 $ - $86,847 $318,871
====== ========= ======== ========= ======== ======== ========
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT.
-5-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(in thousands)
(unaudited)
<TABLE>
<CAPTION>
THREE MONTHS
ENDED MARCH 31,
1999 1998
-------- --------
<S> <C> <C>
Cash flows from operating activities:
Net income............................................................. $ 8,517 $ 6,871
Noncash adjustments:
Depreciation and amortization....................................... 7,856 4,490
Deferred income taxes............................................... 491 2,165
Cash provided by (used in), net of effects of medical practice
transactions, changes in:
Accounts receivable................................................. (21,369) (14,268)
Prepaids and other current assets................................... (5,170) (1,649)
Other assets........................................................ (2,005) -
Accounts payable.................................................... (15,589) (10,241)
Due from/to affiliated physician groups............................. 11,781 7,846
Income taxes payable................................................ 3,520 2,044
Other accrued liabilities........................................... 4,882 2,102
-------- --------
Net cash used in operating activities.............................. (7,086) (640)
-------- --------
Cash flows from investing activities:
Acquisition of property and equipment.................................. (7,743) (6,089)
Net payments in medical practice transactions.......................... (19,966) (7,007)
Other.................................................................. - 41
-------- --------
Net cash used in investing activities.............................. (27,709) (13,055)
-------- --------
Cash flows from financing activities:
Proceeds from credit facility.......................................... 37,000 26,000
Repayment of credit facility........................................... (5,000) -
Repayment of other indebtedness........................................ (3,750) (16,335)
Proceeds from exercise of options...................................... 16 1,813
-------- --------
Net cash provided by financing activities.......................... 28,266 11,478
-------- --------
Decrease in cash and equivalents........................................ (6,529) (2,217)
Cash and equivalents:
Beginning of period.................................................... 10,618 5,000
-------- --------
End of period.......................................................... $ 4,089 $ 2,783
======== ========
Interest paid........................................................... $ 3,763 $ 3,180
Taxes paid.............................................................. 1,500 3
Noncash transactions:
Tax benefit from exercise of non-qualified stock options............... 3,680
Value of Common Stock to be issued in medical practice transactions.... 15,951 1,652
Delivery of Common Stock to be issued in medical practice
transactions......................................................... 5,264 3,197
Debt issued in medical practice transactions........................... 11,516 3,214
Debt assumed in medical practice transactions.......................... 86
Debt issued to finance insurance premiums.............................. 649
</TABLE>
THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THIS STATEMENT.
-6-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(unaudited)
NOTE 1 - BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements have been
prepared in accordance with generally accepted accounting principles for interim
financial reporting and in accordance with Form 10-Q and Rule 10.01 of
Regulation S-X. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, the unaudited condensed
consolidated financial statements contained in this report reflect all
adjustments that are normal and recurring in nature and considered necessary for
a fair presentation of the financial position and the results of operations for
the interim periods presented. The preparation of the Company's financial
statements in conformity with generally accepted accounting principles requires
management to make estimates and assumptions that affect the reported amounts of
assets, liabilities, revenues and expenses, as well as disclosures on contingent
assets and liabilities. Because of inherent uncertainties in this process,
actual future results could differ from those expected at the reporting date.
These unaudited condensed consolidated financial statements, footnote
disclosures and other information should be read in conjunction with the
financial statements and the notes thereto included in the Company's Form
10-K/A-2 filed with the Securities and Exchange Commission on May 7, 1999.
Operating segments
During 1998, the Company adopted Financial Accounting Standards Board (FASB)
Statement No. 131, "Disclosures About Segments of an Enterprise and Related
Information" (FAS 131), which requires reporting of summarized financial results
for the operating segments as well as establishes standards for related
disclosures about products and services, geographic areas and major customers.
The Company evaluates performance based on six different product lines: medical
oncology, radiation oncology, gynecological oncology, stem cell transplantation,
diagnostic radiology, and clinical research. The Company is developing tracking
systems for these product lines. Until the completion of the tracking systems,
it is impractical for the Company to separate operating results for these
product lines. For the first three months of 1999 and 1998, medical oncology
was the only product line that exceeded the reporting thresholds of FAS 131.
The Company, therefore, has used the aggregation criteria of FAS 131 and reports
a single segment.
NOTE 2 - PENDING TRANSACTION
Effective December 11, 1998, the Company entered into a definitive agreement to
merge with Physician Reliance Network, Inc. ("PRN"). As of May 6, 1999, PRN
provided comprehensive management services under long-term agreements to medical
practices comprised of 370 physicians in 13 states. Under the terms of the
merger agreement, holders of PRN common stock will receive a fixed ratio of 0.94
shares of the Company's common stock for each PRN share held. As a result,
stockholders of the Company and PRN will each own approximately 50% of the
combined company on a diluted basis. Following the merger, PRN will be a wholly
owned subsidiary of the Company. In connection with the merger, the Company
will change its name to "US Oncology." The transaction is expected to be
accounted for under the pooling of interests method of accounting and treated as
a tax-free exchange. Closing of the transaction is anticipated on June 15,
1999, subject to stockholder approval of both companies and other customary
conditions. After consummation of the transaction, the Company's financial
statements will be retroactively restated to combine the accounts of the Company
and PRN for all periods presented using their historical basis.
-7-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(unaudited)
NOTE 3 - Medical Service Revenue
Medical service revenue for services to patients by the physician groups
affiliated with the Company is recorded when services are rendered based on
established or negotiated charges reduced by contractual adjustments and
allowances for doubtful accounts. Differences between estimated contractual
adjustments and final settlements are reported in the period when final
settlements are determined. Medical service revenue of the affiliated physician
groups is reduced by amounts retained by the physician groups under the
Company's management services agreements to arrive at the Company's revenue.
The following presents the amounts included in the determination of the
Company's revenue (in thousands):
Three Months
Ended March 31,
-------------------
1999 1998
-------- --------
Medical service revenue.................. $183,843 $133,566
Amounts retained by affiliated physician
groups................................. 44,003 32,617
-------- --------
Revenue.................................. $139,840 $100,949
======== ========
NOTE 4 - MEDICAL PRACTICE TRANSACTIONS
During the first three months of 1999, the Company affiliated with eight
oncology practices. During the first three months of 1998, the Company
affiliated with two oncology practices and acquired two radiation oncology
centers. The transactions have been accounted for as asset purchases. The
following presents the aggregate consideration required to complete those
transactions (in thousands):
Three Months
Ended March 31,
-------------------
1999 1998
-------- --------
Cash and transaction costs.............. $ 19,966 $ 7,007
Liabilities assumed..................... 1,985 895
Issuance of subordinated notes.......... 11,516 2,644
Common Stock to be issued............... 15,951 1,652
--------- --------
$ 49,418 $ 12,198
========= ========
In connection with three medical practice transactions occurring in 1997, the
Company issued subordinated promissory notes contingently obligating the Company
to pay up to $1.3 million. Payment under the promissory notes is contingent on
the Company receiving a defined level of management fees during the first two
years following the applicable medical practice transaction which substantially
exceeds the level of management fees expected by the Company during its
negotiations with the practice. Once the payment is fixed, the subordinated
promissory notes are paid in five annual installments, commencing on the third
anniversary of the medical practice transaction. As of March 31, 1999, the
Company has recorded $334,000 of the $1.3 million (See Note 5, "Subordinated
Notes" herein). The remainder of such liability, if any, will be recorded in
the period in which the outcome of the contingency becomes probable. Any
payment made will be allocated to the affiliated long-term management services
agreement and will be amortized over the remaining life of that asset.
-8-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(unaudited)
NOTE 5 - INDEBTEDNESS
Long-term indebtedness
Long-term indebtedness consists of the following (in thousands):
MARCH 31, December 31,
1999 1998
-------- --------
Subordinated notes........................... $ 89,182 $ 80,611
Credit Facility.............................. 136,000 104,000
Capital lease obligations and other.......... 3,167 3,237
-------- --------
228,349 187,848
Less current maturities...................... 16,525 14,708
-------- --------
$211,824 $173,140
======== ========
Subordinated Notes
The subordinated notes are issued in substantially the same form in different
series and are payable to the physicians with whom the Company has entered into
management services agreements. Substantially all of the notes outstanding at
March 31, 1999 and December 31, 1998 bear interest at 7% per annum, are due in
installments through 2005 and are subordinated to senior bank and certain other
debt. If the Company fails to make a payment under any of the notes, the
respective physician group can terminate the related management service
agreement for cause.
Credit Facility
The Company has a loan agreement and revolving credit/term facility ("Credit
Facility") with First Union National Bank ("First Union") individually and as
Agent for twelve additional lenders ("Lenders). Under the terms of the
agreement, the amount available for borrowing is $150 million through October
31, 2002. Proceeds of loans may be used to finance medical group transactions,
to provide working capital and for other general corporate uses. As of March
31, 1999, the Company had an outstanding balance of $136 million under the
Credit Facility. The Company has classified the Credit Facility as long term
due to its ability and intent to maintain the borrowings past 1999.
Borrowings under the Credit Facility are secured by all capital stock of the
Company's subsidiaries and all material contracts, including management service
agreements. At the Company's option, funds may be borrowed at the Base interest
rate or the London Interbank Offer Rate (LIBOR) up to LIBOR plus an amount
determined under a defined formula. The Base rate is selected by First Union
and is defined as their prime rate or Federal Funds Rate plus 1/2%. Interest on
amounts outstanding under Base rate loans is due quarterly while interest on
LIBOR related loans is due at the end of each applicable interest period or
quarterly, if earlier. As of March 31, 1999, the weighted average interest rate
on all outstanding draws under the Credit Facility was 5.7%.
The Company is subject to restrictive covenants under the Credit Facility,
including the maintenance of certain financial ratios. The agreement limits
certain activities such as incurrence of additional indebtedness, sales of
assets, investments, capital expenditures, mergers and consolidations and the
payment of dividends. Under certain circumstances, additional medical practice
transactions may require First Union's and the Lenders' consent. The proposed
merger with PRN (Note 2) requires consent of the Lenders under the Credit
Facility. The Company is currently negotiating an amendment and restatement of
its Credit Facility that would be effective upon the closing of the merger with
PRN. It is anticipated that, effective upon consummation of the AOR-PRN merger,
the Credit Facility will provide for borrowings of $275 million to $300 million
(including a sub-facility maturing in 364 days). The Company's $75 million
leasing facility would remain in place.
-9-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(unaudited)
Derivatives
As of August 31, 1998, the Company entered into an interest rate swap agreement
with a financial institution to reduce the impact of changes in interest rates
on borrowings under the Credit Facility. The agreement effectively fixed the
interest rate on variable rate debt at a rate of 5.93% per annum for notional
principal amount of $80.0 million through August 30, 1999. The notional amount
of the swap agreement is used to measure the principal amount upon which fixed
rate interest is to be paid or received and does not represent the amount of
exposure to credit loss. The use of this swap agreement had an insignificant
impact on interest expense for the three months ended March 31, 1999.
Master Lease
In December 1997, the Company entered into a $75 million master lease agreement
related to integrated cancer centers. Under the agreement, the lessor purchases
and has title to the properties, pays for the construction costs and thereafter
leases the facilities to the Company. The initial term of the lease is for five
years and can be renewed in one year increments if approved by the lessor. The
lease provides for substantial residual value guarantees and includes purchase
options at original cost on each option. Advances under the master lease
agreement as of March 31, 1999 were $37 million.
NOTE 6 - CAPITALIZATION
As part of entering into long-term management services agreements with physician
practices as described in Note 4, the Company has made nonforfeitable
commitments to issue shares of Common Stock at specified future dates for no
further consideration. Holders of the rights to receive such shares have no
dispositive voting or cash dividend rights with respect to such shares until the
shares have been delivered. Common Stock to be issued is shown as a separate
component in stockholders' equity. The amounts, upon issuance of the shares,
are reclassified to other equity accounts, as appropriate.
The shares of Common Stock to be issued at specified future dates were valued at
the transaction date at a discount from the quoted market price of a delivered
share after considering all relevant factors, including normal discounts for
marketability due to the time delay in delivery of the shares. The discount
for shares of Common Stock to be issued at specified future dates is 10% for
shares to be delivered prior to the fifth anniversary of the transaction and is
20% for shares to be delivered on the fifth anniversary, and thereafter. The
Common Stock in the transactions is to be delivered under the terms of the
respective agreements for periods up to seven years after the initial
transaction date. The recorded value represents management's best estimate of
the fair value of the shares of Common Stock to be delivered in the future as of
the transaction date.
For transactions completed through March 31, 1999, the scheduled issuance of the
shares of Common Stock that the Company is committed to deliver are 4,890,253 in
1999, 4,646,299 in 2000, 1,818,178 in 2001, 2,254,879 in 2002, 891,905 in 2003
and 1,183,183 thereafter.
In March of 1999, options to purchase 1,134,500 shares of Common Stock at $7.70
per share were granted under the Company's various stock option plans, 530,000
of which was granted to executive officers and directors. During the first
three months of 1999, options to purchase 5,900 shares of Common Stock at $3.34
to $8.79 per share were exercised, of which none were exercised by executive
officers and directors. During the first three months of 1999, options to
purchase 39,820 shares of Common Stock were canceled. As of March 31, 1999,
there were options to purchase 7,080,414 shares of Common Stock outstanding
under the Company's various stock option plans at exercise prices of $1.34 to
$24.18 per share.
-10-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(unaudited)
During the first three months of 1999, 375,300 shares of Common Stock were
issued from Treasury Stock in connection with medical practice transactions.
NOTE 7 - EARNINGS PER SHARE
The Company computes earnings per share in accordance with the provisions of
FASB Statement No. 128, "Earnings Per Share", which requires the Company to
disclose "basic" and "diluted" earnings per share (EPS).
The computation of basic EPS is based on a weighted average number of
outstanding shares of Common Stock and Common Stock to be issued during the
periods. The Company includes Common Stock to be issued in both basic and
diluted EPS as there are no foreseeable circumstances that would relieve the
Company of its obligation to issue these shares. The computation of the diluted
EPS is based on a weighted average number of outstanding shares of Common Stock
and Common Stock to be issued during the periods as well as all dilutive
potential Common Stock calculated under the treasury stock method.
The table summarizes the determination of shares used in per share calculations
(in thousands):
<TABLE>
<CAPTION>
Three Months Ended March 31,
----------------------------
1999 1998
------ ------
<S> <C> <C>
Basic
Outstanding at end of period:
Common Stock.................................... 33,576 31,531
Common Stock to be issued....................... 15,685 17,035
------ ------
49,261 48,566
Effect of weighting............................... (43) (607)
------ ------
Shares used in per share calculations........... 49,218 47,959
====== ======
Diluted
Outstanding at end of period:
Common Stock.................................... 33,576 31,531
Common Stock to be issued....................... 15,685 17,035
------ ------
49,261 48,566
Effect of weighting and assumed share
equivalents for grants of stock options and
issuances of stock at less than the weighted
average price................................... 1,287 1,374
------ ------
Shares used in per share calculations............. 50,548 49,940
====== ======
Anti dilutive stock options not included above.... 5,737 3,381
====== ======
</TABLE>
-11-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - CONTINUED
(unaudited)
NOTE 8 - RECENT PRONOUNCEMENTS
In June 1998, FASB issued Statement No. 133, "Accounting for Derivative
Instruments and Hedging Activities," (FAS 133) which is effective for the
Company's financial statements beginning with the first quarter of the year
ending December 31, 2000. FAS 133 requires that an entity recognize all
derivatives as either assets or liabilities in the statement of financial
position and to measure those instruments at fair value. Management does not
expect such implementation to have a material effect on the Company's
operations.
-12-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
Introduction
American Oncology Resources, Inc. (the "Company") is a cancer management company
which provides comprehensive management services under long-term agreements to
its affiliated oncology practices, including operational and clinical research
services and data management, and furnishes personnel, facilities, supplies and
equipment. These affiliated practices provide a broad range of medical services
to cancer patients, integrating the specialties of medical and gynecological
oncology, hematology, radiation oncology, diagnostic radiology and stem cell
transplantation. Substantially all of the Company's revenue consists of
management fees and includes all medical practice operating costs for which the
Company is contractually responsible.
The Company believes that the coordinated delivery of comprehensive cancer care
in an outpatient setting offers high quality care that is more cost-effective
than traditional approaches and is increasingly preferred by patients, payors
and physicians. The Company believes that many oncology practices recognize the
need for outside managerial, financial and business expertise to more
efficiently manage the increasingly complex, burdensome and time-consuming
nonmedical aspects of their practices and that practices will increasingly elect
to enter into management relationships with entities such as the Company.
The Company's objective is to be the leading national cancer management company
providing comprehensive services to an integrated network of affiliated oncology
practices. The Company intends to achieve this objective by (i) focusing
exclusively on oncology, (ii) affiliating with leading oncology practices
throughout the United States, (iii) expanding each affiliated oncology group's
presence in its market, (iv) assisting affiliated oncology practices in offering
coordinated, comprehensive cancer care, (v) negotiating and expanding managed
care relationships and (vi) expanding the clinical research operations of the
affiliated physician groups. Based on the Company's success in expanding its
business to date, the Company believes that it has effective strategies for
achieving its objective of becoming the leading national cancer management
company.
Effective December 11, 1998, the Company entered into a definitive agreement to
merge with Physician Reliance Network, Inc. ("PRN"). As of May 6, 1999, PRN
provided comprehensive management services under long-term agreements to medical
practices comprised of 370 physicians in 13 states. Under the terms of the
merger agreement, holders of PRN common stock will receive a fixed ratio of 0.94
shares on the Company's common stock for each PRN share held. As a result,
stockholders of the Company and PRN will each own approximately 50% of the
combined company on a diluted basis. Following the merger, PRN will be a wholly
owned subsidiary of the Company. In connection with the merger, the Company
will change its name to "US Oncology" The transaction is expected to be
accounted for under the pooling of interests method of accounting and treated as
a tax-free exchange. Closing of the transaction is anticipated on June 15,
1999, subject to stockholder approval of both companies and other customary
conditions. After consummation of the transaction, the Company's financial
statements will be retroactively restated to combine the accounts of the Company
and PRN for all periods presented using their historical basis.
-13-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS - CONTINUED
FORWARD-LOOKING STATEMENTS AND RISK FACTORS
The statements contained in this report, in addition to historical information,
are forward-looking statements based on the Company's current expectations, and
actual results may vary materially. Forward-looking statements often include
words like "believe", "plan", "expect", "intend" or "estimate". The Company's
business and financial results are subject to various risks and uncertainties,
including the Company's continued ability to enter into affiliations with new
physician practices and to successfully integrate such practices, the results of
operations of groups currently affiliated with the Company including results of
operations impacted by changes in cancer therapies or the manner in which cancer
care is delivered, the ability to construct integrated cancer centers and to
operate them profitably, competition, reductions in third-party reimbursement
for services rendered by physician groups affiliated with the Company, health
care regulation and other risks generally affecting the health care industry.
Please refer to the Company's Annual Report on Form 10-K/A-2 for the year ended
December 31, 1998 and subsequent filings with the Securities and Exchange
Commission for a more detailed discussion of such risks and uncertainties. Many
of these risks and uncertainties are beyond the Company's ability to control or
predict. These forward-looking statements are provided as a framework for the
Company's results of operations. The Company does not intend to provide updated
information other than as otherwise required by applicable law.
RESULTS OF OPERATIONS
Since the Company's incorporation in October 1992, the Company has grown rapidly
from managing six affiliated physicians in one state to 381 affiliated
physicians in 18 states as of March 31, 1999. For the three months ended March
31, 1999 and 1998, no affiliated physician group contributed more than 10% of
the Company's revenue. For the first three months of 1999, the payor mix of the
affiliated physician groups' medical practice revenue, expressed as a
percentage, was 37% for Medicare and Medicaid, 46% for managed care and 17% for
private insurance and other payors. For the first three months of 1998, the
payor mix of the affiliated physician groups' medical practice revenue,
expressed as a percentage, was 32% for Medicare and Medicaid, 49% for managed
care, and 19% for private insurance and other payors.
The following table sets forth the percentages of revenue represented by certain
items reflected in the Company's Statement of Operations. The information that
follows should be read in conjunction with the Company's unaudited condensed
consolidated financial statements and notes thereto included elsewhere herein.
THREE MONTHS
ENDED MARCH 31,
-------------------
1999 1998
----- -----
Revenue....................................... 100.0% 100.0%
Operating expenses:
Pharmaceuticals and supplies................ 48.4 44.7
Practice compensation and benefits.......... 18.4 19.3
Other practice costs........................ 10.5 11.7
General and administrative.................. 4.7 5.9
Depreciation and amortization............... 5.6 4.4
Net interest expense........................ 2.6 3.0
----- -----
Income before income taxes.................... 9.8 11.0
Income taxes.................................. 3.7 4.2
----- -----
Net income.................................... 6.1% 6.8%
===== =====
-14-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS - CONTINUED
1999 COMPARED TO 1998
The Company affiliated with eight oncology groups in the first three months of
1999 and two oncology groups and two radiation centers in the first three months
of 1998, respectively. The results of the new affiliated oncology practices are
included in the Company's operating results from the dates of affiliation.
Changes in results of operations for the first three months of 1998 compared to
the first three months of 1999 were caused, in part, by affiliations with these
oncology practices.
Revenue. Revenue increased from $100.9 million in the first three months of
1998 to $139.8 million in 1999, an increase of $38.9 million, or 38.5%. Revenue
for markets under management in 1998 and 1999 increased $30.2 million or 29.8%
over the same period from the prior year. This growth was the result of
expansion of services, increases in patient volume, and recruitment of or
affiliation with additional physicians. The remaining $8.7 million was
attributable to affiliations with oncology practices in new markets.
Pharmaceuticals and Supplies. Pharmaceuticals and supplies, which include
drugs, medications and other supplies used by the affiliated physician groups,
increased from $45.1 for the first three months of 1998 to $67.6 million for the
first three months of 1999, an increase of $22.5 million, or 50.0%. As a
percentage of revenue, pharmaceuticals and supplies increased from 44.7% for the
first three months of 1998 to 48.4% for the comparable period of 1999. This
increase was primarily due to a shift in the revenue mix to a higher percentage
of drug revenue, the introduction of a number of new chemotherapy agents and, to
a lesser extent, lower reimbursement from payors. Management expects that
third-party payors will continue to negotiate the reimbursement rate for
pharmaceuticals and supplies, with the goal of lowering reimbursement rates, and
that such lower reimbursement rates as well as shifts in revenue mix may
continue to adversely impact the Company's margins with respect to such items.
Practice Compensation and Benefits. Practice compensation and benefits, which
include the salaries, wages and benefits of the affiliated physician groups'
employees (excluding affiliated physicians) and the Company's employees who are
located at the affiliated physician practice sites and business offices,
increased from $19.5 million in the first three months of 1998 to $25.8 million
in the first three months of 1999, an increase of $6.3 million or 32.6%. This
increase was principally attributable to the same factors that caused revenue to
increase. As a percentage of revenue, practice compensation and benefits
decreased from 19.3% for the first three months of 1998 to 18.4% for the first
three months of 1999, primarily as a result of regionalization of certain
employee functions.
Other Practice Costs. Other practice costs, which consist of rent, utilities,
repairs and maintenance, insurance and other direct practice costs, increased
from $11.8 million in the first three months of 1998, to $14.7 million in the
first three months of 1999, an increase of $2.9 million or 24.3% over the
comparable prior year period. This increase was principally attributable to the
same factors that caused revenue to increase. As a percentage of revenue, other
practice costs decreased from 11.7% to 10.5%. This decrease is attributable to
economies of scale.
General and Administrative. General corporate expenses increased from $6.0
million in the first three months of 1998 to $6.6 million in the first three
months of 1999, an increase of $0.6 million or 8.9%. This was primarily
attributable to the addition of personnel and greater support costs associated
with the Company's growth since March 31, 1998. As a percentage of revenue,
general and administrative expenses decreased from 5.9% in the first three
months of 1998 to 4.7% in the first three months of 1999 due to economies of
scale.
Depreciation and Amortization. Depreciation and amortization expenses
increased from $4.5 million in the first three months of 1998 to $7.9 million in
the first three months of 1999, an increase of $3.4 million or 75.0%. As a
percentage of revenue, depreciation and amortization expense increased from 4.4%
in the first three months of 1998 to 5.6% in the first three months of 1999.
This increase was primarily the result of changing the amortization period on
management services agreements from 40 years to 25 years, as well as investments
in equipment and management information systems.
-15-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS - CONTINUED
Interest. Net interest expense increased from $3.0 million in the first three
months of 1998, to $3.5 million in the first three months of 1999, an increase
of $0.5 million or 19.7%. The increase was the result of higher levels of debt,
principally incurred to finance transactions with seventeen oncology groups
since March 31, 1998. As a percentage of revenue, net interest expense
decreased from 3.0% in the first three months of 1998 to 2.6% in the first three
months of 1999. Indebtedness to physicians increased from approximately $81.9
million at March 31, 1998 to $89.1 million at March 31, 1999.
Income Taxes. Income tax expense increased from the prior year as a result of
the Company's increased profitability. For the first three months of 1999 the
Company recognized a tax provision of $5.2 million resulting in an effective tax
rate of 38.0%, which was unchanged from the same period of 1998.
Net Income. Net income increased from $6.9 million in the first three months
of 1998 to $8.5 million in the first three months of 1999, an increase of $1.6
million or 23.2%. As a percentage of revenue, net income declined from 6.8% to
6.1% principally as a result of the decrease in the amortization period for
management services agreements from 40 years to 25 years effective July 1, 1998,
and to a lesser extent, the introduction of a number of new, lower margin
chemotherapy agents. In response to this decline, the Company has adopted
several strategies. Most importantly, the Company has formed a number of
preferred pharmaceutical relationships and continues to pursue others. In
addition, the Company routinely considers and implements measures to control
general and administrative costs to enable it to achieve greater economies of
scale. Lastly, the Company seeks opportunities to expand its business in areas
that are less affected by lower pharmaceutical margins, such as radiation
oncology, clinical research and data management. The Company believes that its
results of operations and financial condition have benefited from each of these
strategies.
LIQUIDITY AND CAPITAL RESOURCES
The Company requires capital primarily to enter into management services
agreements with, and to purchase the nonmedical assets of, medical and radiation
oncology practices. During the first three months of 1999, the Company paid
total consideration of $49.4 million in connection with affiliations with eight
physician groups including cash and transaction costs of $20.0 million. During
the comparable period of the prior year, the Company paid $12.2 million for
affiliations with two physician groups and two radiation oncology centers,
including cash and transaction costs of $7.0 million.
To fund its growth and development, the Company has satisfied its transaction
and working capital needs through debt and equity financings and borrowings
under a $150 million syndicated revolving credit facility ("Credit Facility")
with First Union National Bank of North Carolina ("First Union"), as agent for
the various lenders. In addition, as part of the Credit Facility, the Company
has obtained a $75 million end-loaded leasing facility that is related to its
integrated cancer centers.
During the first three months of 1999, the Company borrowed $32 million, net,
under the Credit Facility to fund medical practice transactions and the
acquisition of property and equipment. Borrowings under the Credit Facility
bear interest at a rate equal to a rate based on prime rate or the London
Interbank Offer Rate, based on a defined formula. The Credit Facility contains
affirmative and negative covenants, including the maintenance of certain
financial ratios, restrictions on sales, leases or other dispositions of
property, restrictions on other indebtedness and prohibitions on the payment of
dividends. The Company's management services agreements, and the capital stock
of the Company's subsidiaries are pledged as security under the Credit Facility.
The Company is currently in compliance with the Credit Facility covenants, with
additional capacity under the Credit Facility of $14.0 million at March 31,
1999. The Company has relied primarily on management fees received from its
affiliated physician groups to fund its operations.
-16-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS - CONTINUED
Cash used in operations was $7.1 million in the first three months of 1999, an
increase of $6.5 million from 1998. The increase was due to merger related
expenditures and the timing of certain working capital payments. Cash used in
investing activities was $27.7 million for the first three months of 1999, an
increase of $14.7 million from the same period of 1998. Such increase is due
primarily to greater activity in medical practice transactions in 1999. Cash
provided by financing activities was $28.3 million for the first three months of
1999, an increase of $16.8 million from the comparable prior year period. Such
increase is due to a $14.0 million one-time payment in 1998 relating to a
medical practice transaction. In addition, incremental borrowings of $6.0
million under the Credit Facility were incurred in the first three months of
1999 to fund the medical practice transaction activity noted above.
As of March 31, 1999, the Company had net working capital of $98.0 million and
cash and cash equivalents of $4.1 million. The Company's also had $90.5 million
of current liabilities, including approximately $16.5 million of long-term
indebtedness maturing before March 31, 2000. The Company currently expects that
its principal use of funds in the near future will be in connection with
anticipated medical practice transactions, merger expenses and purchases of
medical equipment.
The Company is currently negotiating an amendment and restatement of its
Credit Facility that would be effective upon the closing of the merger with PRN.
It is anticipated that, effective upon consummation of the AOR-PRN merger, the
Credit Facility will provide for borrowings of $275 million to $300 million
(including a sub-facility maturing in 364 days). The Company's $75 million
leasing facility would remain in place. In connection with the negotiation of
the amended and restated Credit Facility, the Company has noted that the credit
market for physician practice management companies has significantly weakened;
fewer lenders are willing to lend to the Company at rates historically available
to it. Although the Company currently believes it will be able to secure the
proposed financing under the amended and restated Credit Facility, there can be
no assurance it will be able to do so on favorable terms. If the Company is
unable to secure additional financing in the future, its ability to pursue its
growth strategy of affiliating with oncology groups and constructing cancer
centers may be adversely impacted.
YEAR 2000 ISSUE
The "Year 2000 problem" describes computer programs that use two rather than
four digits to define the applicable year, and thus cannot distinguish between
the year 1900 and the year 2000. These programs are present in the Company's
computer systems and are incorporated into equipment. The Company's computer
hardware and software, building infrastructure components (e.g., alarm systems
and HVAC systems) and medical equipment (e.g., linear accelerators, which are
used to provide radiation therapy) that are date sensitive may contain programs
with the Year 2000 problem. If uncorrected, the problem could result in
computer system and program failure or equipment malfunctions that could disrupt
business operations.
-17-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS - CONTINUED
Project. The Company has divided its Year 2000 Project into six phases:
development, awareness, assessment, remediation, validation and implementation.
In connection with its Year 2000 Project, the Company is assessing information
technology software and hardware, medical equipment, third-party payors and
third-party suppliers. The Company's strategy also includes development of
contingency plans to address potential disruption of operations arising from the
Year 2000 problems.
Information Systems. The Company recognizes that investment in information
systems and state-of-the-art medical equipment is integral to its operations.
The majority of the Company's technology expenditures for 1998 and 1999 relate
to the development and implementation of a clinical information system. This
system provides an interactive electronic format for capturing the spectrum of
patient care and creates an electronic medical record. This system is believed
to be Year 2000 compliant. The costs of the clinical information system are
expected to be capitalized and amortized over the life of the asset.
In 1994, the Company began a project to replace the existing practice
management systems (billing and collection systems) with a common system to
improve efficiency and consistency among its affiliated practices. This
practice management system is beginning to be implemented in the second quarter
of 1999. Any remaining practice management systems not replaced by the new
system during the first half of 1999 are Year 2000 compliant. Costs to upgrade
the practice management systems that are not converted to the commons system
would be expensed; however, such costs are not expected to be material.
In 1996, the Company's management incorporated a business strategy to
accommodate the rapid growth of its operations. One component of this strategy
was the investment in developing an integrated financial system throughout its
network of affiliated physicians. This financial system is believed to be Year
2000 compliant and has been implemented in two locations. The Company intends
to complete the implementation of this financial system throughout its network
of affiliated practices by the fourth quarter of 1999. The costs incurred in
developing such a financial system have been capitalized through the initial
implementation date.
Medical Equipment. The Company has reviewed the Year 2000 readiness of the
linear accelerators and associated equipment used in the affiliated radiation
oncology practices. The suppliers of the medical equipment have certified
that, with minor upgrades, these systems will be Year 2000 compliant. These
systems are being upgraded during the first and second quarters of 1999. The
Company is in the process of evaluating the Year 2000 compliance of other
clinical equipment at this time and expects to complete this process by mid-
1999. Any such costs to upgrade equipment will be expensed.
Third-Party Payors. The Company bills and collects for medical services from
numerous third party payors in operating its business. These third parties
include fiscal intermediaries on behalf of the Medicare program, as well as
insurance companies, HMOs and other private payors. As part of the Company's
Year 2000 strategy, a comprehensive survey has been sent to all significant
payors to assess their timeline for Year 2000 compliance and the impact to the
Company. The Company is in the process of assembling and analyzing these
questionnaires.
Third-Party Suppliers. The Company is currently evaluating third party
vendors of medical supplies and pharmaceuticals in order to determine whether
their services and products will be interrupted or malfunction due to the Year
2000 problem. The Company's pharmaceutical ordering system is a proprietary
system developed by a third party vendor and is utilized under the Company's
purchasing contract with such vendor. This relationship has been identified and
prioritized as the most critical in the vendor evaluation process. The third
party vendor is currently upgrading its pharmaceuticals purchase ordering system
at no cost to the Company. The upgraded software is expected to be certified as
Year 2000 compliant by the vendor and is scheduled for implementation by the
second quarter of 1999.
-18-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS - CONTINUED
Risks. The failure to correct a material Year 2000 problem could result in an
interruption in, or failure of, certain normal business activities or
operations. Such failures could materially and adversely affect the Company's
results of operations, liquidity and financial condition. Due to the general
uncertainty inherent in the Year 2000 problem, resulting in part from the
uncertainty of the Year 2000 readiness of third-party payors and third-party
suppliers, the Company is unable to determine at ths time whether the
consequences of Year 2000 failures will have a material impact on the Company's
results of operations, liquidity or financial condition. The Company's Year
2000 project is expected to significantly reduce the Company's level of
uncertainty about the Year 2000 problem and, in particular, about the Year 2000
compliance and readiness of its payors and suppliers.
Costs. The Company estimates that total costs to be incurred in the execution
of its Year 2000 Project are approximately $4.1 million, including approximately
$600,000 relating to laboratory and medical equipment upgrades and replacements.
The Company estimates that approximately $2.3 million of the costs will be
capitalized and amortized over the useful life of the assets as they reprresent
new applications and expanded capabilities.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS.
In the normal course of business, the financial position of the Company is
routinely subjected to a variety of risks. Among these risks is the market risk
associated with interest rate movements on outstanding debt. The Company
regularly assesses these risks and has established policies and business
practices to protect against the adverse effects of these and other potential
exposures.
The Company's borrowings under the Credit Facility and subordinated notes due
to affiliated physicians contain an element of market risk from changes in
interest rates. The Company manages this risk, in part, through the use of
interest rate swaps, as explained in Note 5 of the Company's Consolidated
Financial Statements. The Company does not enter into interest rate swaps or
hold other derivative financial instruments for speculative purposes.
For purposes of specific risk analysis, the Company uses sensitivity analysis
to determine the impact that market risk exposures may have on the Company. The
financial instruments included in the sensitivity analysis consist of all of the
Company's cash and equivalents, long-term and short-term debt and all derivative
financial instruments.
To perform sensitivity analysis, the Company assesses the risk of loss in fair
values from the impact of hypothetical changes in interest rates on market
sensitive instruments. The market values for interest rate risk are computed
based on the present value of future cash flows as impacted by the changes in
the rates attributable to the market risk being measured. The discount rates
used for the present value computations were selected based on market interest
rates in effect at March 31, 1999. The market values that result from these
computations are compared with the market values of these financial instruments
at March 31, 1999. The differences in this comparison are the hypothetical
gains or losses associated with each type of risk. A one percent increase or
decrease in the levels of interest rates on variable rate debt with all other
variables held constant would not result in a material change to the Company's
results of operations or financial position or the fair value of its financial
instruments.
-19-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
PART II. OTHER INFORMATION
ITEM 2. Changes in Securities
In connection with each affiliation transaction between the Company and a
physician group, the Company purchases the nonmedical assets of, and enters into
a long-term management services agreement with, that physician group. In
consideration for that arrangement, the Company typically pays cash, issues
subordinated promissory notes (in general, payable in equal installments on the
third through seventh anniversaries of the closing date at an annual interest
rate of seven percent) and unconditionally agrees to deliver shares of Common
Stock at future specified dates (in general, on each of the third through fifth
anniversaries of the closing date). The price per share is the lower of the
average of the closing price per share for the five days preceding the date of
the letter of intent or the closing date with respect to such affiliation
transaction.
The following table describes all unregistered sales by the Company of the
Company's securities during the first three months of 1999. Each sale was a
private placement made in connection with a physician transaction, as described
in general in the preceding paragraph. The overwhelming majority of the
affiliated physicians are accredited investors. No underwriter was involved in
any such sale, and no commission or similar fee was paid with respect thereto.
Each sale was not registered under the Securities Act of 1933 in reliance on
Section 4(2) of such Act and Rule 506 enacted thereunder.
<TABLE>
<CAPTION>
Number of Shares Aggregate Principal
Date of Transaction Number of Physicians of Common Stock(1) Amount of Notes
------------------- -------------------- ------------------ -------------------
<S> <C> <C> <C>
1/99 8 819,665 $6,316,000
1/99 4 283,568 2,558,000
1/99 2 47,611 233,000
1/99 1 24,426 640,000
1/99 1 18,609 186,000
1/99 1 96,366 680,000
2/99 1 12,881 217,000
3/99 1 33,381 686,000
</TABLE>
(1) In connection with each affiliation transaction, the Company unconditionally
agrees to deliver shares of Common Stock at specified future dates.
-20-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
OTHER INFORMATION - CONTINUED
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
Exhibit
Number Description
------ -----------
3.1 Certificate of Incorporation, as amended (incorporated by
reference from Form 10-Q for the period ended March 31, 1997)
3.2 By-Laws, as amended (incorporated by reference from Form 10-Q for
the period ended March 31, 1997)
4.1 Rights Agreement between the Company and American Stock Transfer
& Trust Company (incorporated by reference from Form 8-A filed
June 2, 1997)
27 Financial Data Schedule
(b) Reports on Form 8-K
During the first quarter of 1999, the Company did not file any Current
Reports on Form 8-K.
-21-
<PAGE>
AMERICAN ONCOLOGY RESOURCES, INC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: May 17, 1999 AMERICAN ONCOLOGY RESOURCES, INC.
By: /s/ R. DALE ROSS
----------------------------------
R. Dale Ross, Chairman of the Board
and Chief Executive Officer
By: /s/ L. FRED POUNDS
----------------------------------
L. Fred Pounds, Vice President of Finance
and Chief Financial Officer
-22-
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1999
<PERIOD-START> JAN-01-1999
<PERIOD-END> MAR-31-1999
<CASH> 4,089
<SECURITIES> 0
<RECEIVABLES> 158,406
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 188,419
<PP&E> 83,210
<DEPRECIATION> 25,231
<TOTAL-ASSETS> 632,621
<CURRENT-LIABILITIES> 90,461
<BONDS> 211,824
0
0
<COMMON> 336
<OTHER-SE> 318,535
<TOTAL-LIABILITY-AND-EQUITY> 632,621
<SALES> 0
<TOTAL-REVENUES> 139,840
<CGS> 0
<TOTAL-COSTS> 122,561
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 3,602
<INCOME-PRETAX> 13,737
<INCOME-TAX> 5,220
<INCOME-CONTINUING> 8,517
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 8,517
<EPS-PRIMARY> .17
<EPS-DILUTED> .17
</TABLE>
